RxDoctor Payments DataLook up a doctor →

Alan Parsa, MD

Endocrinology, Diabetes & Metabolism · Honolulu, HINPI 1215268362

Payments from drug & device makers

$4,107,021in general payments, 2019–2025

Across 1,520 payments — averaging $2701.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$3.2M
  • Dexcom, Inc.$157K
  • AbbVie$149K
  • Lilly USA, LLC$137K
  • Novo Nordisk$136K
  • Corcept Therapeutics$101K
  • plus $264K from 25 others
$185,694in research payments, 2019–2025

Across 12 payments — averaging $15,475 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$186K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,107,021 in reported general payments places this provider in the 95th percentile of 22 endocrinology, diabetes & metabolism providers in Hawaii.

See all endocrinology, diabetes & metabolism providers in Hawaii

Medicare billing

Part B allowed, 2024
$138,320
Medicare patients
547
Services billed
1,242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →